tiprankstipranks
Advertisement
Advertisement

Perseus Proteomics Narrows Losses but Withholds Full-Year Forecast Amid Ongoing Cash Burn

Story Highlights
  • Perseus Proteomics grew nine-month sales but stayed in the red, posting a narrower per-share loss.
  • Assets and equity declined, no dividends were declared, and management withheld a full-year forecast.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Perseus Proteomics Narrows Losses but Withholds Full-Year Forecast Amid Ongoing Cash Burn

Meet Samuel – Your Personal Investing Prophet

Perseus Proteomics, Inc. ( (JP:4882) ) has shared an update.

Perseus Proteomics reported net sales of ¥103 million for the nine months ended December 31, 2025, a 24.1% year-on-year increase, but remained loss-making with an operating loss of ¥573 million and a net loss of ¥547 million. Basic loss per share improved to ¥37.14 from ¥49.20 a year earlier, while shareholders’ equity ratio declined to 60.9% as total assets and net assets fell, and the company again decided not to pay dividends and refrained from issuing a full-year forecast due to the difficulty of making a rational earnings prediction.

The balance sheet weakened compared with the previous fiscal year-end, with total assets dropping to ¥1,322 million and shareholders’ equity decreasing to ¥805 million, signaling continued cash burn as development spending weighs on results. Management left its dividend forecast unchanged at zero and cited uncertainty in its operating environment for not providing guidance, underscoring ongoing financial risk for shareholders despite incremental top-line growth and a slight narrowing of losses.

The most recent analyst rating on (JP:4882) stock is a Hold with a Yen228.00 price target. To see the full list of analyst forecasts on Perseus Proteomics, Inc. stock, see the JP:4882 Stock Forecast page.

More about Perseus Proteomics, Inc.

Perseus Proteomics Inc., listed on the Tokyo Stock Exchange under code 4882, operates in the biotechnology and life sciences sector, focusing on proteomics-driven research and development. The company’s business model centers on generating revenue from its proprietary technologies and pipelines, while it continues to invest heavily in R&D, resulting in a financial profile characterized by modest sales and recurring operating losses.

Average Trading Volume: 274,052

Technical Sentiment Signal: Sell

Current Market Cap: Yen3.51B

For detailed information about 4882 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1